SG Americas Securities LLC Decreases Holdings in Amneal Pharmaceuticals, Inc. $AMRX

SG Americas Securities LLC decreased its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 9.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 710,876 shares of the company’s stock after selling 73,927 shares during the quarter. SG Americas Securities LLC owned approximately 0.23% of Amneal Pharmaceuticals worth $8,836,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of AMRX. Oliver Luxxe Assets LLC purchased a new stake in shares of Amneal Pharmaceuticals during the fourth quarter worth approximately $1,972,000. Artemis Investment Management LLP purchased a new stake in shares of Amneal Pharmaceuticals during the fourth quarter worth $1,574,000. Envestnet Asset Management Inc. purchased a new position in shares of Amneal Pharmaceuticals in the third quarter worth about $1,608,000. Citigroup Inc. boosted its position in Amneal Pharmaceuticals by 55.7% during the third quarter. Citigroup Inc. now owns 282,862 shares of the company’s stock worth $2,831,000 after acquiring an additional 101,166 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in Amneal Pharmaceuticals by 75.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 3,761,739 shares of the company’s stock valued at $47,398,000 after acquiring an additional 1,611,698 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Performance

Amneal Pharmaceuticals stock opened at $17.23 on Friday. The company’s 50 day simple moving average is $13.82 and its 200-day simple moving average is $13.40. Amneal Pharmaceuticals, Inc. has a 1 year low of $7.66 and a 1 year high of $17.86. The company has a market capitalization of $5.50 billion, a price-to-earnings ratio of 45.34 and a beta of 1.30.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%.The company had revenue of $722.52 million for the quarter. Equities analysts expect that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. UBS Group assumed coverage on Amneal Pharmaceuticals in a report on Friday, April 17th. They set a “buy” rating and a $19.00 target price on the stock. Weiss Ratings lowered Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, May 26th. Zacks Research downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Barclays boosted their price target on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th. Finally, Truist Financial raised their price objective on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $15.80.

Insider Transactions at Amneal Pharmaceuticals

In related news, Director Deborah M. Autor sold 34,819 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $12.94, for a total transaction of $450,557.86. Following the completion of the transaction, the director directly owned 93,660 shares in the company, valued at $1,211,960.40. This trade represents a 27.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 17.30% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.